Concerning Fungal Coinfections in COVID-19: Risks, Types, and Prevention – A Review

Bala Krishnan A  ¹, Vinoth Kumar K K ¹, Tharanikumar L ¹, M. Shajini G Inbakani ¹

The review highlights the alarming rise of fungal infections like Mucormycosis among COVID-19 patients, necessitating prompt diagnosis and care to prevent fatalities.

Abstract

The characteristics of certain fungal infections, including fever, cough, and shortness of breath, may be similar to COVID-19. Laboratory tests are needed to establish whether an individual has a COVID-19 fungal infection. Any patient can experience COVID-19 and simultaneously a fungal infection. People with serious COVID-19 are especially vulnerable to bacterial or fungal infections, such as those in intensive care units (ICUs). Aspergillosis (ASP), invasive candidiasis, is among the most frequent fungal infections in COVID-19 patients. The increased prevalence of these fungal coinfections may be linked with serious disorders and deaths. Knowledge of the potential for fungal coinfection is important to minimize delays in diagnosis and care to help avoid serious diseases and mortality due to these infections.

Keywords: COVID-19, Black fungus, White fungus, Symptoms, Preventive measures.

References

Adegbola  (2012). Childhood pneumonia as a global health priority and the strategic interest of the Bill & Melinda Gates Foundation. Clinical infectious diseases, 54(suppl_2), S89-S92.

Allaw et al (2021). First Candida auris Outbreak during a COVID-19 Pandemic in a Tertiary-Care Center in Lebanon. Pathogens, 10(2), 157.

Basso et al (2021). COVID-19-associated histoplasmosis in an AIDS patient. Mycopathologia, 186(1), 109-112.

Brissot et al (2021). Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Bone marrow transplantation, 56(3), 532-535.

Chen et al (2021). Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate. Biochimica et Biophysica Acta (BBA)-General Subjects, 1865(6), 129893.

Chi et al (2020). Beyond COVID-19: A Whole of Health Look at Impacts During the Pandemic Response.

Chohan (2020). After the Coronavirus Vaccine’s Discovery: Concerns Regarding a COVID-19 Vaccination’s Distribution.

Chohan (2020). Economics in a Pandemic: Observations from the First Six Months of Coronavirus.

Das, R. C. Management of COVID-19 Through Strategic Roles of Governments: A Study on Highly Affected Countries. Management Strategies to Survive in a Competitive Environment: How to Improve Company Performance, 275.

Das, R. C. Management of COVID-19 Through Strategic Roles of Governments: A Study on Highly Affected Countries. Management Strategies to Survive in a Competitive Environment: How to Improve Company Performance, 275.

Erku et al (2021). When fear and misinformation go viral: Pharmacists' role in deterring medication misinformation during the'infodemic'surrounding COVID-19. Research in Social and Administrative Pharmacy, 17(1), 1954-1963.

Excler et al (2021). Vaccine development for emerging infectious diseases. Nature medicine, 1-10.

Garg et al (2021). Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia, 1-10.

Gholipour et al (2021). COVID-19 infection risk from exposure to aerosols of wastewater treatment plants. Chemosphere, 273, 129701.

Hassard et al (2021). Innovation in wastewater near-source tracking for rapid identification of COVID-19 in schools. The Lancet Microbe, 2(1), e4-e5.

https://www.bbc.com/future/article/20210519-mucormycosis-the-black-fungus-hitting-indias-covid-patients

https://www.livemint.com/news/india/as-mucormycosis-cases-rise-in-india-aiims-director-lists-key-factors-to-prevent-black-fungus-11621592318715.html

https://www.theguardian.com/world/2021/may/21/mucormycosis-black-fungus-disease-linked-covid-spreads-india

Jamka et al (2019). Accelerating typhoid conjugate vaccine introduction: what can be learned from prior new vaccine introduction initiatives?. Clinical Infectious Diseases, 68(Supplement_2), S171-S176.

John et al (2021). When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis. Journal of Fungi, 7(4), 298.

Kanwar et al (2021). A Fatal Case of Rhizopus azygosporus Pneumonia Following COVID-19. Journal of Fungi, 7(3), 174.

Khurana et al (2021). Profile of coinfections & secondary infections in COVID-19 patients at a dedicated COVID-19 facility of a tertiary care Indian hospital: Implication on antimicrobial resistance. Indian journal of medical microbiology, 39(2), 147-153.

Kumar et al (2021). SARS-CoV-2 antibodies in healthcare workers in a large university hospital, Kerala, India. Clinical Microbiology and Infection, 27(3), 481-483.

Marimuthu et al (2021). HIV and SARS CoV-2 coinfection: A retrospective, record-based, case series from South India. Journal of medical virology, 93(1), 163-165.

Mohindra et al (2021). COVID-19 infection in a HIV positive health care worker: first case report from a tertiary care hospital of North India. VirusDisease, 1-5.

Moorthy et al (2021). SARS-CoV-2, Uncontrolled Diabetes and Corticosteroids—An Unholy Trinity in Invasive Fungal Infections of the Maxillofacial Region? A Retrospective, Multi-centric Analysis. Journal of Maxillofacial and Oral Surgery, 1-8.

Mussini et al (2021). Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT). Clinical Microbiology and Infection, 27(3), 389-395.

Noushad and Al-Saqqaf (2021). COVID-19 case fatality rates can be highly misleading in resource-poor and fragile nations: the case of Yemen. Clinical Microbiology and Infection, 27(4), 509-510.

Pilato et al (2021). Molecular Epidemiological Investigation of a Nosocomial Cluster of C. auris: Evidence of Recent Emergence in Italy and Ease of Transmission during the COVID-19 Pandemic. Journal of Fungi, 7(2), 140.

Prestel et al (2021). Candida auris outbreak in a COVID-19 specialty care unit—Florida, July–August 2020. Morbidity and Mortality Weekly Report, 70(2), 56.

Salmanton-García et al (2021). COVID-19–associated pulmonary aspergillosis, March–August 2020. Emerging infectious diseases, 27(4), 1077.

Sen et al (2021). Mucor in a viral land: A tale of two pathogens. Indian journal of ophthalmology, 69(2), 244.

Sim et al(2021). Costs of immunization programs for 10 vaccines in 94 low-and middle-income countries from 2011 to 2030. Value in Health, 24(1), 70-77.

Soin et al (2021). Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. The Lancet Respiratory Medicine, 9(5), 511-521.

Thompson and Kalkowska (2021). Potential future use, costs, and value of poliovirus vaccines. Risk Analysis, 41(2), 349-363.

Toh et al (2021). Human papillomavirus vaccination after COVID-19. JNCI Cancer Spectrum, 5(2), pkab011.

Torner (2020). Collateral effects of Covid-19 pandemic emergency response on worldwide immunizations. Vacunas (English Edition), 21(2), 73.

Wang et al (2021). Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19. Journal of thrombosis and thrombolysis, 51(3), 657-662.